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Introduction
Brain arteriovenous malformations (BAVMs) can cause intracranial hemorrhage (ICH), the primary reason for poor outcomes from these lesions. The principal goal of BAVM treatment is to eliminate the risk of hemorrhage by complete removal or obliteration of the nidus while minimizing procedural risk. Treatment should be performed only when the expected natural history of the lesion exceeds therapeutic risk. Depending on BAVM features, embolization, radiosurgery, excision, or a combination of these treatments may be most appropriate. Microsurgery is widely used and provides the most immediate and durable results as it relates to ICH reduction risk. Some lesions cannot, however, be resected without significant morbidity, though high-risk features, such as associated aneurysms, may still be treated selectively to help reduce the risk of hemorrhage. Aneurysms occur commonly, found in 36% of BAVMs in recently published large cohort studies. 1, 2 This study evaluates targeted embolization of aneurysms associated with BAVMs without subsequent resection.
Methods
Under institutional review board-approved protocols, retrospective analysis was performed of procedure databases at two academic medical centers with highvolume neurointerventional radiology services. All patients with BAVMs with associated aneurysms-both flow-related feeding artery and intranidal-who underwent treatment between July 1996 and June 2015 were identified. From this group, patients undergoing targeted embolization of an aneurysm without intention for subsequent resection were selected for further analysis. The final decision against operative management was made by the microvascular neurosurgeon involved in each patient's care. Targeted aneurysm embolization was defined as embolization intended to occlude only the BAVM-associated aneurysm. Aneurysms occluded during more extensive embolization targeting a feeding artery or AVM nidus at large were excluded as the current analysis sought to evaluate targeted embolization alone. Patients undergoing further BAVM treatment with stereotactic radiosurgery after embolization were included.
Procedural and medical records were reviewed to gather demographic and lesion characteristics. Procedure success was defined as complete occlusion of the aneurysm without associated non-target embolization or other procedural complication. Any complications were noted, as were any symptoms they caused.
Clinical follow-up data were reviewed to identify rates of adverse events, defined as ICH, new onset of seizures, or death. Cumulative time to events and annualized rate of adverse events were calculated for comparison to previously reported rates. Additionally, modified Rankin scale (mRS) values were imputed from clinical records at presentation and 30 days, 90 days, and one year after treatment and at the point of last contact. Chi-square tests were performed to identify effects of patient, lesion, or treatment factors on outcomes.
Results
Thirty-two patients met inclusion criteria out of 1103 patients with BAVMs evaluated with diagnostic cerebral angiography at the two institutions during the study period. Patient and lesion characteristics are summarized in Table 1 . Patient age at diagnosis ranged from 4.0 to 86.3 years (mean 43.1, SD 23.1). Twenty-seven (84.4%) were acutely ruptured at time of diagnosis, with the aneurysm believed to be the source of hemorrhage in all cases. Five lesions (15.6%) caused seizures. Twenty-four (75.0%) lesions involved eloquent territory. Ten (31.3%) BAVMs had diffuse nidus architecture. In addition to these factors, many patients were deemed poor surgical candidates because of advanced age and other risk factors. Equal numbers of lesions were treated with intranidal aneurysms versus feeding artery aneurysms (16 patients each).
Embolization was performed with Onyx in 13 patients (40.6%), coils in 13 patients (40.6%), N-butyl-cyano-acrylate (n-BCA) in four patients (12.5%), and ethanol in two patients (6.3%). Successful occlusion of the targeted aneurysm was achieved in all 32 patients, and the treatment was achieved in a single procedure in all cases. Four (12.5%) procedural complications occurred: two aneurysm ruptures during treatment, one dissection requiring no treatment, and one thrombus successfully treated with abciximab. No new clinical symptoms resulted from these technical complications.
Follow-up data were available for a total of 101.3 patient-years. One patient who initially presented with hemorrhage experienced repeated hemorrhage 1911 days after embolization. This hemorrhage occurred from the AVM nidus; no aneurysm was visualized during evaluation at repeat hemorrhage. An additional patient who initially presented with hemorrhage developed new seizures 30 days after treatment. Additionally, one patient died of causes not related to the BAVM or its treatment 577 days after embolization. The remaining 31 patients had improved mRS at last contact. This study thus yielded annualized rates of hemorrhage after treatment of 1.0% and adverse events after treatment as defined in the study methods of Arteriovenous Malformations (ARUBA) trial sought to identify such lesions, but this has raised more questions than answers because of limitations in methodology, difficulties with patient enrollment, and relatively short follow-up interval for lesions that present a hemorrhagic risk for the remainder of a patient's life. 3 Multiple studies on the natural history of BAVMs have reported various rates of hemorrhage. [4] [5] [6] [7] [8] [9] The most comprehensive evidence to date is offered by two recent meta-analyses. 6, 10 Among all BAVMs, an overall annual rupture rate of 2.3% and 3.0% were found. 6, 10 However, ruptured malformations had an annual rate of repeat rupture of 4.5% and 4.8% versus an annual rupture risk of 1.3% and 2.2% for unruptured lesions. 6, 10 Furthermore, repeat hemorrhage rates are not static, as risk of repeat hemorrhage is highest in the first year after initial hemorrhage, with rates ranging from 6% to 15% annually. 4, 5, [7] [8] [9] [10] Several other lesion traits affect hemorrhage risk in addition to rupture status, including the presence of associated aneurysms. 2, 6, [11] [12] [13] The Gross and Du meta-analysis found a hazard ratio of 1.8 for the presence of aneurysms associated with BAVMs, and the Kim et al. meta-analysis found a hazard ratio of 1.58 for aneurysms with respect to repeat hemorrhage within one year. 6, 10 Published rates of rupture range from 6.9% to 9.8% for lesions with associated aneurysms versus 2.4%-5.3% for lesions without aneurysms. 4, 6, [14] [15] [16] The impact of aneurysm location on rupture rates is unclear, as some studies have shown higher risk with intranidal aneurysms while other research identified higher risk with aneurysms of the feeding arteries. 2, 4, 11, 14, 17 The location of aneurysms was not likely to dramatically affect outcomes in our current cohort as an equal number of feeding artery and intranidal aneurysms were found. This corresponds well with the grossly equal number of aneurysm types in the recent meta-analyses. 6, 10 To eliminate risk of hemorrhage, complete obliteration of the BAVM nidus must be achieved. This can be accomplished by surgical resection, although factors such as involvement of eloquent parenchyma, size, diffuseness of the nidus, deep venous drainage, and the patient's age increase the morbidity of surgery. 18, 19 Stereotactic radiosurgery can lead to lesion obliteration, although this occurs in a delayed fashion, and hemorrhage risk matches or may exceed the natural history risk during the latency period prior to obliteration. 20, 21 Additionally, determining the appropriate radiosurgical dose requires balancing the need for sufficient dose to induce nidus obliteration while limiting risk of side effects like radiation necrosis, hemorrhage, and neurological defects. 22 Transcatheter embolization may also be used to treat these lesions, although current trends in care largely use embolization in the preoperative setting to reduce surgical morbidity. 23 While curative embolization has been advocated, procedural morbidity has been reported at 2%-20% with mortality occurring in 1%-2% of procedures. [24] [25] [26] [27] [28] [29] [30] [31] At most centers, transcatheter therapies are followed by further treatment with surgery or radiosurgery since persistent arteriovenous shunting necessarily entails persistent rupture risk. Additionally, alterations in lesion hemodynamics may increase hemorrhage risk, particularly if venous outflow is occluded but arterial supply persists.
Despite optimizing multimodality treatment techniques, there remain lesions for which curative treatment is impossible or prohibitively morbid. While some practitioners argue that no treatment is suitable for such lesions, others believe intervention can still play a positive role. 3, 23, 32 Rupture risks can be lowered if embolization is targeted at high-risk features. 26, [32] [33] [34] [35] [36] [37] The specific features most commonly targeted include aneurysms and venous ectasia or stenosis. A recent study identified reduced rates of hemorrhage in the setting of venous ectasia and no difference with associated venous stenosis; these are no longer considered features suitable for targeted therapy in our hospitals' practice. 38 Two studies retrospectively examining targeted embolization for associated aneurysms found lower rates of hemorrhage after such treatment compared to expected rates of hemorrhage predicted by natural history studies. 26, 35 Additionally, technical success and complication rates were similar to those of AVM embolization procedures in general. 26, 35 The previously reported results of targeted endovascular treatment examined embolization of the arterial pedicle with the high-risk feature. 26, [32] [33] [34] [35] [36] In the current series, we examined treatments in which only the aneurysm itself was targeted. Such targeted treatment may secure the aneurysm without significantly altering the flow dynamics of these high-risk inoperable lesions. In our review, we found two general groups for which such treatment seems appropriate: The first is younger patients in whom stereotactic radiosurgery is the optimal treatment, but securing a ruptured aneurysm is required prior to radiosurgery (Figure 1) ; the other group is elderly patients or individuals with significant risk factors for surgery that make resection untenable ( Figure 2 ). We believe securing aneurysms in these patients returns their hemorrhagic risk to more acceptable levels at which no further treatment is acutely warranted.
The procedural complication rate in this series of 12.5% is at the upper end of rates published in recent large series of embolization of BAVMs. [39] [40] [41] [42] [43] [44] Additionally, the absence of symptoms resulting from any of these complications and technical success in all procedures is encouraging, suggesting that such treatments can be considered both acceptably safe and effective. This argument is reinforced by the reduced risk of hemorrhage following targeted embolization compared to natural history data. Since our cohort included both ruptured and unruptured lesions with aneurysms, relevant annual hemorrhage risks would range from 6.9% to 15%; patients treated in this series had an annual hemorrhage rate of 1.0%. 2, 46, [11] [12] [13] [14] [15] 17 Indeed, this point is further strengthened when considering the rate of any adverse event (hemorrhage, new seizure, or death from any cause), which was far below the lower bound of expected hemorrhagic risk (3.0% versus 6.9%).
The current analysis has several limitations, including its retrospective nature. Additionally, there is selection bias in a study examining only individuals selected for a certain treatment. This small study was not adequately powered to compare targeted embolization of AVM-associated aneurysms against other treatment approaches for AVMs. Further analysis is warranted to compare this treatment approach to others in patients with similar lesions. Owing to the heterogeneity of these lesions and the multiple options for treatments, further prospective analysis and better natural history data are needed. The BAVM continued to fill with drainage through the cortical vein (arrowhead, (d)). Because of deep basal ganglia location, resection was not performed. The patient underwent treatment with stereotactic radiosurgery. All neurological deficits resolved, and there has been no additional hemorrhage. CT: computed tomography; MCA: middle cerebral artery; BAVM: brain arteriovenous malformation.
Conclusion
BAVMs can cause substantial morbidity and mortality, most of which is driven by ICH. Treatment of these lesions can be difficult, and the appropriate treatment is not always clear. Targeted embolization of aneurysms associated with BAVMs can be performed safely and can reduce the risk of subsequent hemorrhage below that which can be expected without intervention. Such treatment should be considered for lesions for which resection is not possible. Figure 2 . An octogenarian was found down and intubated in the field. Non-contrast CT (a) demonstrated diffuse subarachnoid hemorrhage. CTA (not pictured) suggested a cerebellar BAVM, so the patient was taken to angiography following placement of an external ventricular drain. Digital subtraction angiography (b) in the early arterial phase demonstrated two flow-related aneurysms (white arrows) of the superior cerebellar artery upstream to a superolateral cerebellar BAVM (nidus-black arrow, draining vein-black arrowhead). Posttreatment angiography (c) in the late arterial phase demonstrates no residual filing of the two aneurysms following coiling (white arrows). The superior cerebellar artery remains patent (white arrowheads), and the BAVM continues to fill (nidus-black arrow, draining vein-black arrowhead). CT: computed tomography; CTA: computed tomography angiography; BAVM: brain arteriovenous malformation.
